Advertisement

Too many women are dying from cervix cancer: Problems and solutions

  • David K. Gaffney
    Correspondence
    Corresponding author at: 1950 Circle of Hope, Room 1570, Salt Lake City, UT 84112, United States of America.
    Affiliations
    Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84103, United States of America

    Department of Radiation Oncology, University of Utah School of Medicine, 1950 Circle of Hope, Rm 1570, Salt Lake City, UT 84112, United States of America
    Search for articles by this author
  • Mia Hashibe
    Affiliations
    Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84103, United States of America

    Division of Public Health, Department of Family and Preventative Medicine, University of Utah School of Medicine, 375 Chipeta Way, Suite. A, Salt Lake City, UT 84108, United States of America
    Search for articles by this author
  • Deanna Kepka
    Affiliations
    Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84103, United States of America

    College of Nursing, University of Utah, 10 South 2000 East, Salt Lake City, UT 84112, United States of America
    Search for articles by this author
  • Kathryn A. Maurer
    Affiliations
    Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84103, United States of America

    Department of Obstetrics and Gynecology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132, United States of America
    Search for articles by this author
  • Theresa L. Werner
    Affiliations
    Huntsman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84103, United States of America

    Division of Oncology, Department of Medicine, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT 84132, United States of America
    Search for articles by this author
Published:October 06, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.10.004

      Highlights

      • Patient education and expansion of nontraditional screening programs for unscreened and underscreened populations.
      • Implement reduction in costs, government health programs, and school based programs for vaccinations.
      • Adhere to guidelines, ensure access to healthcare, and establish an ethnically similar physician workforce for all patients.
      • Improve training, work efficiencies, payment reform, and quality metrics.
      • Ensure widespread use of chemoradiation, identify targets, and develop mutation-specific trials.

      Abstract

      One woman dies from cervix cancer every 2 min, adding up to over 270,000 deaths globally per year. This cancer affects a young population, and hence, the loss of life is staggering. There are many aspects of prevention, screening, and care that are suboptimal. A great deal is known about HPV induced carcinogenesis, yet clinical outcomes have been stagnant over decades. There has been no improvement in cervix cancer survival in the US since the mid-1970s [
      • Siegel R.L.
      • Miller K.D.
      • Jemal A.
      Cancer statistics, 2018.
      ]. With increased knowledge of the disease and greater worldwide resources including prevention, screening, and improved therapeutics, there is significant promise for fewer women to die from this virally induced cancer. We focus here on the major problems in prevention, screening, and delivery of care for cervix cancer and provide concrete solutions. With appropriate focus, a major improvement in survival from cervix cancer could be achieved in a short time span.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J. Clin. 2018; 68: 7-30
        • Committee on Practice B-G
        ACOG practice bulletin number 131: screening for cervical cancer.
        Obstet. Gynecol. 2012; 120: 1222-1238
        • Benard V.B.
        • Thomas C.C.
        • King J.
        • Massetti G.M.
        • Doria-Rose V.P.
        • Saraiya M.
        • et al.
        Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007–2012.
        MMWR Morb. Mortal. Wkly Rep. 2014; 63: 1004-1009
        • Watson M.
        • Benard V.
        • King J.
        • Crawford A.
        • Saraiya M.
        National assessment of HPV and pap tests: changes in cervical cancer screening, National Health Interview Survey.
        Prev. Med. 2017; 100: 243-247
        • Watson M.
        • Benard V.
        • Flagg E.W.
        Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003–2014.
        Prev. Med. Rep. 2018; 9: 124-130
        • Ronco G.
        • Dillner J.
        • Elfstrom K.M.
        • Tunesi S.
        • Snijders P.J.
        • Arbyn M.
        • et al.
        Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.
        Lancet. 2014; 383: 524-532
        • van Rosmalen J.
        • de Kok I.M.
        • van Ballegooijen M.
        Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
        BJOG. 2012; 119: 699-709
        • Mayrand M.H.
        • Duarte-Franco E.
        • Rodrigues I.
        • Walter S.D.
        • Hanley J.
        • Ferenczy A.
        • et al.
        Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
        N. Engl. J. Med. 2007; 357: 1579-1588
        • Castle P.E.
        • Lorincz A.T.
        • Mielzynska-Lohnas I.
        • Scott D.R.
        • Glass A.G.
        • Sherman M.E.
        • et al.
        Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.
        J. Clin. Microbiol. 2002; 40: 1088-1090
        • Wright Jr., T.C.
        • Stoler M.H.
        • Behrens C.M.
        • Apple R.
        • Derion T.
        • Wright T.L.
        The ATHENA human papillomavirus study: design, methods, and baseline results.
        Am. J. Obstet. Gynecol. 2012; 206: 46e1
        • Huh W.K.
        • Ault K.A.
        • Chelmow D.
        • Davey D.D.
        • Goulart R.A.
        • Garcia F.A.
        • et al.
        Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
        Gynecol. Oncol. 2015; 136: 178-182
        • Ogilvie G.S.
        • van Niekerk D.
        • Krajden M.
        • Smith L.W.
        • Cook D.
        • Gondara L.
        • et al.
        Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial.
        JAMA. 2018; 320: 43-52
        • Belinson J.L.
        • Du H.
        • Yang B.
        • Wu R.
        • Belinson S.E.
        • Qu X.
        • et al.
        Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing.
        Int. J. Cancer. 2012; 130: 1855-1860
        • Wright Jr., T.C.
        • Denny L.
        • Kuhn L.
        • Pollack A.
        • Lorincz A.
        HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
        JAMA. 2000; 283: 81-86
        • Arbyn M.
        • Verdoodt F.
        • Snijders P.J.
        • Verhoef V.M.
        • Suonio E.
        • Dillner L.
        • et al.
        Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
        Lancet Oncol. 2014; 15: 172-183
        • Lenselink C.H.
        • de Bie R.P.
        • van Hamont D.
        • Bakkers J.M.
        • Quint W.G.
        • Massuger L.F.
        • et al.
        Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening.
        J. Clin. Microbiol. 2009; 47: 2564-2570
        • Gonzalez P.
        • Cortes B.
        • Quint W.
        • Kreimer A.R.
        • Porras C.
        • Rodriguez A.C.
        • et al.
        Evaluation of the FTA carrier device for human papillomavirus testing in developing countries.
        J. Clin. Microbiol. 2012; 50: 3870-3876
        • Gustavsson I.
        • Lindell M.
        • Wilander E.
        • Strand A.
        • Gyllensten U.
        Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV.
        J. Clin. Virol. 2009; 46: 112-116
        • Levinson K.L.
        • Abuelo C.
        • Salmeron J.
        • Chyung E.
        • Zou J.
        • Belinson S.E.
        • et al.
        The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible.
        Gynecol. Oncol. 2013; 129: 318-323
        • Maurer K.
        • Luo H.
        • Shen Z.
        • Wang G.
        • Du H.
        • Wang C.
        • et al.
        Evaluation of a new solid media specimen transport card for high risk HPV detection and cervical cancer prevention.
        J. Clin. Virol. 2016; 76: 14-19
        • Anderson C.
        • Breithaupt L.
        • Des Marais A.
        • Rastas C.
        • Richman A.
        • Barclay L.
        • et al.
        Acceptability and ease of use of mailed HPV self-collection among infrequently screened women in North Carolina.
        Sex. Transm. Infect. 2018; 94: 131-137
        • Levinson K.L.
        • Jernigan A.M.
        • Flocke S.A.
        • Tergas A.I.
        • Gunderson C.C.
        • Huh W.K.
        • et al.
        Intimate partner violence and barriers to cervical cancer screening: a gynecologic oncology fellow research network study.
        J. Low. Genit. Tract Dis. 2016; 20: 47-51
        • Sewali B.
        • Okuyemi K.S.
        • Askhir A.
        • Belinson J.
        • Vogel R.I.
        • Joseph A.
        • et al.
        Cervical cancer screening with clinic-based Pap test versus home HPV test among Somali immigrant women in Minnesota: a pilot randomized controlled trial.
        Cancer Med. 2015; 4: 620-631
        • Smith J.S.
        • Des Marais A.C.
        • Deal A.M.
        • Richman A.R.
        • Perez-Heydrich C.
        • Yen-Lieberman B.
        • et al.
        Mailed human papillomavirus self-collection with Papanicolaou test referral for infrequently screened women in the United States.
        Sex. Transm. Dis. 2018; 45: 42-48
        • de Martel C.
        • Ferlay J.
        • Franceschi S.
        • Vignat J.
        • Bray F.
        • Forman D.
        • et al.
        Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.
        Lancet Oncol. 2012; 13: 607-615
        • Organization WH
        Guidelines for the Prevention and Control of Cervical Cancer.
        (Available from)
        • Senkomago V.
        • Duran D.
        • Loharikar A.
        • Hyde T.B.
        • Markowitz L.E.
        • Unger E.R.
        • et al.
        CDC activities for improving implementation of human papillomavirus vaccination, cervical Cancer screening, and surveillance worldwide.
        Emerg. Infect. Dis. 2017; 23
        • Gavi
        About Gavi, the Vaccine Alliance.
        (Available from)
        • Bruni L.
        • Diaz M.
        • Barrionuevo-Rosas L.
        • Herrero R.
        • Bray F.
        • Bosch F.X.
        • et al.
        Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
        Lancet Glob. Health. 2016; 4: e453-e463
        • Collange F.
        • Fressard L.
        • Pulcini C.
        • Sebbah R.
        • Peretti-Watel P.
        • Verger P.
        General practitioners' attitudes and behaviors toward HPV vaccination: a French national survey.
        Vaccine. 2016; 34: 762-768
        • Hanson K.E.
        • Koch B.
        • Bonner K.
        • McRee A.L.
        • Basta N.E.
        National trends in parental HPV vaccination intentions and reasons for hesitancy, 2010–2015.
        Clin. Infect. Dis. 2018; 67: 1018-1026
        • Ladner J.
        • Besson M.H.
        • Audureau E.
        • Rodrigues M.
        • Saba J.
        Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009–2014.
        BMC Health Serv. Res. 2016; 16: 575
        • Williams W.W.
        • Lu P.J.
        • Saraiya M.
        • Yankey D.
        • Dorell C.
        • Rodriguez J.L.
        • et al.
        Factors associated with human papillomavirus vaccination among young adult women in the United States.
        Vaccine. 2013; 31: 2937-2946
        • Walker T.Y.
        • Elam-Evans L.D.
        • Singleton J.A.
        • Yankey D.
        • Markowitz L.E.
        • Fredua B.
        • et al.
        National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2016.
        MMWR Morb. Mortal. Wkly Rep. 2017; 66: 874-882
        • Bodson J.
        • Wilson A.
        • Warner E.L.
        • Kepka D.
        Religion and HPV vaccine-related awareness, knowledge, and receipt among insured women aged 18-26 in Utah.
        PLoS One. 2017; 12e0183725
        • Lee L.Y.
        • Garland S.M.
        Human papillomavirus vaccination: the population impact.
        F1000 Res. 2017; 6: 866
        • Henley S.J.
        • Anderson R.N.
        • Thomas C.C.
        • Massetti G.M.
        • Peaker B.
        • Richardson L.C.
        Invasive cancer incidence, 2004-2013, and deaths, 2006-2015, in nonmetropolitan and metropolitan counties - United States.
        MMWR Surveill. Summ. 2017; 66: 1-13
        • Beavis A.L.
        • Gravitt P.E.
        • Rositch A.F.
        Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States.
        Cancer. 2017; 123: 1044-1050
        • Barrington D.A.
        • Dilley S.E.
        • Landers E.E.
        • Thomas E.D.
        • Boone J.D.
        • Straughn Jr., J.M.
        • et al.
        Distance from a Comprehensive Cancer Center: a proxy for poor cervical cancer outcomes?.
        Gynecol. Oncol. 2016; 143: 617-621
        • Rauh-Hain J.A.
        • Melamed A.
        • Schaps D.
        • Bregar A.J.
        • Spencer R.
        • Schorge J.O.
        • et al.
        Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.
        Gynecol. Oncol. 2018; 149: 4-11
        • Robin T.P.
        • Amini A.
        • Schefter T.E.
        • Behbakht K.
        • Fisher C.M.
        Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.
        Gynecol. Oncol. 2016; 143: 319-325
        • Pfaendler K.S.
        • Chang J.
        • Ziogas A.
        • Bristow R.E.
        • Penner K.R.
        Disparities in adherence to national comprehensive cancer network treatment guidelines and survival for stage IB-IIA cervical cancer in California.
        Obstet. Gynecol. 2018; 131: 899-908
        • Brookfield K.F.
        • Cheung M.C.
        • Lucci J.
        • Fleming L.E.
        • Koniaris L.G.
        Disparities in survival among women with invasive cervical cancer: a problem of access to care.
        Cancer. 2009; 115: 166-178
        • Uppal S.
        • Chapman C.
        • Spencer R.J.
        • Jolly S.
        • Maturen K.
        • Rauh-Hain J.A.
        • et al.
        Association of hospital volume with racial and ethnic disparities in locally advanced cervical cancer treatment.
        Obstet. Gynecol. 2017; 129: 295-304
        • Farley J.H.
        • Hines J.F.
        • Taylor R.R.
        • Carlson J.W.
        • Parker M.F.
        • Kost E.R.
        • et al.
        Equal care ensures equal survival for African-American women with cervical carcinoma.
        Cancer. 2001; 91: 869-873
        • Coutard H.
        The results and methods of treatment of cancer by radiation.
        Ann. Surg. 1937; 106: 584-598
        • Anker C.J.
        • Cachoeira C.V.
        • Boucher K.M.
        • Rankin J.
        • Gaffney D.K.
        Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy.
        Int. J. Radiat. Oncol. Biol. Phys. 2010; 76: 704-712
        • Mazeron R.
        • Castelnau-Marchand P.
        • Escande A.
        • Rivin Del Campo E.
        • Maroun P.
        • Lefkopoulos D.
        • et al.
        Tumor dose-volume response in image-guided adaptive brachytherapy for cervical cancer: a meta-regression analysis.
        Brachytherapy. 2016; 15: 537-542
        • Han K.
        • Milosevic M.
        • Fyles A.
        • Pintilie M.
        • Viswanathan A.N.
        Trends in the utilization of brachytherapy in cervical cancer in the United States.
        Int. J. Radiat. Oncol. Biol. Phys. 2013; 87: 111-119
        • Rose P.G.
        • Bundy B.N.
        • Watkins E.B.
        • Thigpen J.T.
        • Deppe G.
        • Maiman M.A.
        • et al.
        Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
        N. Engl. J. Med. 1999; 340: 1144-1153
        • Gill B.S.
        • Lin J.F.
        • Krivak T.C.
        • Sukumvanich P.
        • Laskey R.A.
        • Ross M.S.
        • et al.
        National cancer data base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
        Int. J. Radiat. Oncol. Biol. Phys. 2014; 90: 1083-1090
        • Georg D.
        • Kirisits C.
        • Hillbrand M.
        • Dimopoulos J.
        • Potter R.
        Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy.
        Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 1272-1278
        • Tanderup K.
        • Lindegaard J.C.
        • Kirisits C.
        • Haie-Meder C.
        • Kirchheiner K.
        • de Leeuw A.
        • et al.
        Image guided adaptive brachytherapy in cervix cancer: a new paradigm changing clinical practice and outcome.
        Radiother. Oncol. 2016; 120: 365-369
        • Han K.
        • Viswanathan A.N.
        Brachytherapy in gynecologic cancers: why is it underused?.
        Curr. Oncol. Rep. 2016; 18: 26
        • Compton J.J.
        • Gaspar L.E.
        • Shrieve D.C.
        • Wilson L.D.
        • Griem K.L.
        • Amdur R.J.
        • et al.
        Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs.
        Brachytherapy. 2013; 12: 622-627
        • Eifel P.J.
        • Ho A.
        • Khalid N.
        • Erickson B.
        • Owen J.
        Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study.
        Int. J. Radiat. Oncol. Biol. Phys. 2014; 89: 249-256
        • Grover S.
        • Harkenrider M.M.
        • Cho L.P.
        • Erickson B.
        • Small C.
        • Small Jr., W.
        • et al.
        Image guided cervical brachytherapy: 2014 survey of the American brachytherapy society.
        Int. J. Radiat. Oncol. Biol. Phys. 2016; 94: 598-604
        • Petereit D.G.
        • Frank S.J.
        • Viswanathan A.N.
        • Erickson B.
        • Eifel P.
        • Nguyen P.L.
        • et al.
        Brachytherapy: where has it gone?.
        J. Clin. Oncol. 2015; 33: 980-982
        • Bauer-Nilsen K.
        • Hill C.
        • Trifiletti D.M.
        • Libby B.
        • Lash D.H.
        • Lain M.
        • et al.
        Evaluation of delivery costs for external beam radiation therapy and brachytherapy for locally advanced cervical cancer using time-driven activity-based costing.
        Int. J. Radiat. Oncol. Biol. Phys. 2018; 100: 88-94
        • Fyles A.
        • Keane T.J.
        • Barton M.
        • Simm J.
        The effect of treatment duration in the local control of cervix cancer.
        Radiother. Oncol. 1992; 25: 273-279
        • Moore K.N.
        • Java J.J.
        • Slaughter K.N.
        • Rose P.G.
        • Lanciano R.
        • DiSilvestro P.A.
        • et al.
        Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG oncology/gynecologic oncology group ancillary data analysis.
        Gynecol. Oncol. 2016; 143: 294-301
        • Monk B.J.
        • Sill M.W.
        • DS McMeekin
        • Cohn D.E.
        • Ramondetta L.M.
        • Boardman C.H.
        • et al.
        Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study.
        J. Clin. Oncol. 2009; 27: 4649-4655
        • Kitagawa R.
        • Katsumata N.
        • Shibata T.
        • Kamura T.
        • Kasamatsu T.
        • Nakanishi T.
        • et al.
        Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505.
        J. Clin. Oncol. 2015; 33: 2129-2135
        • Tewari K.S.
        • Sill M.W.
        • Long 3rd, H.J.
        • Penson R.T.
        • Huang H.
        • Ramondetta L.M.
        • et al.
        Improved survival with bevacizumab in advanced cervical cancer.
        N. Engl. J. Med. 2014; 370: 734-743
        • Tewari K.S.
        • Monk B.J.
        New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
        Clin. Cancer Res. 2014; 20: 5349-5358
        • Boussios S.
        • Seraj E.
        • Zarkavelis G.
        • Petrakis D.
        • Kollas A.
        • Kafantari A.
        • et al.
        Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review.
        Crit. Rev. Oncol. Hematol. 2016; 108: 164-174
        • McLachlan J.
        • Boussios S.
        • Okines A.
        • Glaessgen D.
        • Bodlar S.
        • Kalaitzaki R.
        • et al.
        The impact of systemic therapy beyond first-line treatment for advanced cervical cancer.
        Clin. Oncol. (R. Coll. Radiol.). 2017; 29: 153-160
        • Scatchard K.
        • Forrest J.L.
        • Flubacher M.
        • Cornes P.
        • Williams C.
        Chemotherapy for metastatic and recurrent cervical cancer.
        Cochrane Database Syst. Rev. 2012; 10: CD006469
        • Cancer Genome Atlas Research N
        • Albert Einstein College of M
        • Analytical Biological S
        • Barretos Cancer H
        • Baylor College of M
        • Beckman Research Institute of City of H
        • et al.
        Integrated genomic and molecular characterization of cervical cancer.
        Nature. 2017; 543: 378-384
        • Alexandrov L.B.
        • Nik-Zainal S.
        • Wedge D.C.
        • Aparicio S.A.
        • Behjati S.
        • Biankin A.V.
        • et al.
        Signatures of mutational processes in human cancer.
        Nature. 2013; 500: 415-421
        • Le D.T.
        • Durham J.N.
        • Smith K.N.
        • Wang H.
        • Bartlett B.R.
        • Aulakh L.K.
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413
        • Hollebecque A.
        • Meyer T.
        • Moore K.N.
        • Machiels J.-P.H.
        • Greve J.D.
        • López-Picazo J.M.
        • et al.
        An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.
        J. Clin. Oncol. 2017; 35: 5504
        • Administration USFaD
        FDA Approves Pembrolizumab for Advanced Cervical Cancer With Disease Progression During or After Chemotherapy.
        (updated 06/13/2018 Available from)
        • Atun R.
        • Jaffray D.A.
        • Barton M.B.
        • Bray F.
        • Baumann M.
        • Vikram B.
        • et al.
        Expanding global access to radiotherapy.
        Lancet Oncol. 2015; 16: 1153-1186
        • Carlson R.W.
        • Scavone J.L.
        • Koh W.J.
        • McClure J.S.
        • Greer B.E.
        • Kumar R.
        • et al.
        NCCN framework for resource stratification: a framework for providing and improving global quality oncology care.
        J. Natl. Compr. Cancer Netw. 2016; 14: 961-969
        • Chuang L.T.
        • Temin S.
        • Camacho R.
        • Duenas-Gonzalez A.
        • Feldman S.
        • Gultekin M.
        • et al.
        Management and care of women with invasive cervical cancer: American society of clinical oncology resource-stratified clinical practice guideline.
        J. Glob. Oncol. 2016; 2: 311-340
        • Suneja G.
        • Brown D.
        • Chang A.
        • Erickson B.
        • Fidarova E.
        • Grover S.
        • et al.
        American brachytherapy society: brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries.
        Brachytherapy. 2017; 16: 85-94
        • Ryu S.Y.
        • Lee W.M.
        • Kim K.
        • Park S.I.
        • Kim B.J.
        • Kim M.H.
        • et al.
        Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
        Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: e577-e581
      1. Estimated Cervical Cancer Incidence Worldwide in 2012 [Available from: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.